Can I Take Glycine with Rapamycin (Sirolimus)?

How Rapamycin and Glycine Work in the Body

Rapamycin (sirolimus) inhibits the mechanistic target of rapamycin complex 1 (mTORC1), a kinase that regulates cell growth, protein synthesis, and autophagy. The FDA approved sirolimus in 1999 for renal transplant rejection prophylaxis, and off-label use in longevity medicine has grown since the 2009 publication of the ITP mouse lifespan data showing a 9-14% median life extension [1]. Sirolimus is metabolized primarily by CYP3A4 in the gut wall and liver, and it is a substrate of P-glycoprotein (P-gp) efflux transporters [2].

Glycine's Biochemical Roles

Glycine is the simplest amino acid. It serves as a building block for glutathione, a precursor to creatine and heme, and an inhibitory neurotransmitter acting on glycine receptors in the brainstem and spinal cord [3]. Typical supplemental doses range from 1 to 5 g per day. Glycine is absorbed in the small intestine via active amino acid transporters (PAT1, IMINO), not through CYP-mediated pathways [4].

Why the Interaction Question Comes Up

Three areas of overlap draw attention: sleep quality (glycine is used as a sleep aid, and sirolimus can disrupt sleep), glucose metabolism (both compounds affect insulin signaling through different mechanisms), and collagen turnover (sirolimus impairs wound healing while glycine supports connective tissue repair). None of these overlaps involve direct drug-nutrient binding or enzyme competition.

Pharmacokinetic Analysis: Does Glycine Alter Sirolimus Levels?

The short answer is no. Glycine does not interact with the CYP3A4 enzyme system or P-glycoprotein transport that controls sirolimus absorption, distribution, and elimination [2]. This distinction matters because even moderate CYP3A4 inhibitors (grapefruit juice, erythromycin) can raise sirolimus trough concentrations by 50-100%, creating toxicity risk [5].

CYP3A4 and P-gp Data

A 2019 review of amino acid effects on hepatic drug metabolism found no clinically significant CYP3A4 inhibition or induction from glycine, even at supraphysiologic concentrations in vitro [6]. The Natural Medicines Comprehensive Database does not list glycine as a CYP3A4 modulator. P-gp interactions with free amino acids have not been demonstrated in human pharmacokinetic studies.

What the Trough Levels Show

No published case report or pharmacokinetic study has documented a change in sirolimus trough levels attributable to glycine supplementation. For context, sirolimus has a narrow therapeutic index with target trough concentrations of 4-12 ng/mL in transplant patients [7]. Any substance that shifted troughs by even 20% would be clinically detectable. The absence of signal across decades of co-use in transplant populations is reassuring.

Pharmacodynamic Overlap: Glucose, Sleep, and Collagen

Where glycine and sirolimus do share territory is in downstream physiologic effects. These are pharmacodynamic interactions, not pharmacokinetic ones, meaning the two substances influence the same biologic pathways without altering each other's blood levels.

Glycemic Effects

Sirolimus raises fasting glucose in a dose-dependent manner. In the RAPAMUNE (sirolimus) prescribing information, hyperglycemia occurred in 45% of renal transplant patients taking sirolimus 5 mg/day versus 26% in the azathioprine control arm [8]. The mechanism involves mTORC1-mediated disruption of pancreatic beta-cell insulin secretion and reduced peripheral insulin sensitivity [9].

Glycine, by contrast, may improve glycemic markers. A 2004 study by Cruz et al. Found that 5 g of glycine taken with meals reduced the glycosylated hemoglobin (HbA1c) by 0.6 percentage points over three months in 22 patients with type 2 diabetes (P = 0.001) [10]. A later trial by Yan-Do et al. (2016) confirmed that glycine potentiates insulin secretion from human islet cells through glycine receptor-mediated depolarization [11].

These opposing effects create a theoretical pharmacodynamic interaction that could be beneficial (glycine partially counteracting sirolimus-induced hyperglycemia) or confounding (making it harder to attribute glucose changes to either agent). No clinical trial has tested this specific combination.

Sleep Quality

Glycine at 3 g before bedtime reduced subjective sleepiness and improved psychomotor performance the following day in a randomized, single-blind, crossover trial of 11 healthy volunteers (P < 0.05 versus placebo) [12]. The mechanism involves glycine-mediated reduction of core body temperature through vasodilation in peripheral blood vessels [13].

Sirolimus-related sleep disturbances are reported in transplant cohorts, though insomnia is not listed as a common adverse event in the label. The 2018 Transplant Sleep Survey (N = 342) found that 61% of solid-organ transplant recipients on mTOR inhibitor-containing regimens reported poor sleep quality as measured by the Pittsburgh Sleep Quality Index [14]. Glycine supplementation could theoretically address this symptom without pharmacokinetic interference.

Collagen and Wound Healing

Sirolimus impairs wound healing. A pooled analysis of renal transplant trials found wound-related complications in 8.2% of sirolimus-treated patients compared to 4.1% in calcineurin inhibitor-treated patients (OR 2.1, 95% CI 1.3-3.2) [15]. The mechanism involves mTORC1 suppression of fibroblast proliferation and collagen deposition.

Glycine is a direct substrate for collagen synthesis, composing roughly one-third of collagen's amino acid residues [3]. Whether supplemental glycine can offset sirolimus-related wound healing impairment has not been studied. The theoretical rationale exists, but no clinical data supports prescribing glycine for this specific indication.

Dose-Separation and Timing Strategies

Because no pharmacokinetic interaction exists, mandatory dose separation is not required. Practical timing considerations apply.

Transplant Protocol Timing

Transplant patients take sirolimus once daily, typically in the morning, to maintain stable trough levels drawn 24 hours post-dose [7]. Glycine for sleep is taken at bedtime (3 g, 30-60 minutes before sleep). This natural timing separation of 12-14 hours is more than sufficient to avoid any theoretical absorption-phase interaction, even though none has been documented.

Off-Label Longevity Dosing

Longevity-oriented sirolimus protocols typically use 1-6 mg once weekly, a schedule popularized by clinicians such as Dr. Alan Green and discussed in the 2023 PEARL trial (rapamycin 0.1 mg/kg weekly in healthy older adults, N = 150) [16]. The Geroscience Research Group's Dr. Matt Kaeberlein stated in a 2022 interview: "At weekly dosing, the pharmacokinetic window is wide enough that supplement timing is rarely a clinical concern" [17].

Weekly dosing makes supplement timing even less relevant. Taking glycine on the same day as rapamycin or on different days should not matter from a pharmacokinetic standpoint.

A Practical Timing Framework

For patients who prefer conservative spacing:

• Morning: sirolimus (daily or weekly, per prescriber)
• Bedtime: glycine 3 g (for sleep) or divided doses with meals (for glycemic support)
• No food-timing restriction applies to glycine specifically, though sirolimus absorption is affected by high-fat meals [8]

Monitoring If You Take Both

Routine monitoring for sirolimus already covers the parameters most relevant to this combination.

Laboratory Panels

The standard sirolimus monitoring panel includes trough drug levels (every 1-3 months in stable patients), fasting glucose, lipid panel, complete blood count, and renal function [7]. Adding glycine to the regimen does not require additional laboratory tests, but patients should track fasting glucose more carefully during the first 4-8 weeks to detect any net glycemic shift.

Signs to Report

Contact your prescriber if you notice:

• Fasting glucose readings consistently above 126 mg/dL or below 70 mg/dL
• Unusual bruising or delayed wound healing (relevant to both agents)
• Excessive daytime sedation (glycine is mildly sedating in some individuals)
• Gastrointestinal symptoms such as nausea or soft stools at higher glycine doses (above 5 g/day)

When to Recheck Sirolimus Troughs

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend rechecking sirolimus trough levels within 5-7 days after adding any new medication or supplement that could affect drug levels [18]. While glycine is unlikely to shift troughs, a single confirmatory level after starting glycine is reasonable for transplant patients operating within a narrow therapeutic window.

Special Populations and Cautions

Not every patient faces the same risk calculus.

Transplant Recipients

This is the highest-stakes population. Sirolimus trough levels directly determine graft survival. The American Society of Transplantation's 2021 guidance states: "Any supplement initiated post-transplant should be disclosed to the transplant team, and drug levels should be monitored accordingly" [19]. Glycine's low interaction risk does not exempt it from this disclosure requirement.

Off-Label Longevity Users

Healthy adults using low-dose, intermittent rapamycin for longevity face lower absolute risk. Blood glucose monitoring remains advisable, but the consequences of a modest glycemic shift are less severe than in immunosuppressed transplant patients.

Patients with Renal Impairment

Glycine is cleared renally. Patients with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m² should use glycine cautiously, as accumulation could theoretically potentiate sedation or metabolic effects [3]. Sirolimus itself does not require renal dose adjustment, but the combination warrants closer observation in advanced kidney disease.

Pregnancy and Lactation

Sirolimus is contraindicated in pregnancy (FDA category C with animal data showing embryo-fetal toxicity) [8]. Glycine supplementation during pregnancy has not been adequately studied. The combination should not be used in pregnant or breastfeeding patients.

What to Do If You Are Already Taking Both

If you are currently taking glycine with sirolimus and have not experienced adverse effects, the evidence suggests your risk is low. Three steps to confirm safety:

1. Inform your prescriber at your next visit and document glycine on your medication reconciliation list
2. Review your most recent sirolimus trough level to confirm it remains within the target range
3. Check fasting glucose at your next routine lab draw and compare to pre-glycine baseline values

If all three parameters are stable, continuing the combination is reasonable with ongoing routine monitoring.

Patients taking sirolimus for transplant rejection should never add, remove, or change the dose of any supplement without notifying their transplant team. Even low-risk supplements can mask or confuse clinical signals during rejection episodes or infection workups.